Buying property worth over Rs 50 lakh? Then pay TDS before registering it, or income tax sleuths will come knocking on your door.
The TDS (Tax Deducted at Source) kicks in from June 1 with the implementation of Section 194-IA, announced in the finance budget of 2013-14. As per this section, the buyer should provide TDS documents on transfer or sale of immovable property (mainly land or house) other than agricultural land, before registering the property. The sub-registrars act as check-posts, if such transactions take place and TDS documents are not provided. This is applicable only if the transaction is Rs 50 lakh or above.
This was made clear at a workshop organized by the IT department and the stamps and registration department, to educate sub-registrars on TDS provision on the sale of immovable property, on 11th June.
Of the total transaction, 1% is TDS and 1% is levied as stamp duty, but in case the seller doesn?t provide PAN documents or gives an invalid PAN, the buyer should deduct 20% tax instead of 1%.
S Ravi, director-general of income tax (investment), said: ?Sub-registrars ensure that PAN numbers and the permanent address of the seller should be available because many a time, in case of tax evasion and property sale, the original land owner is untraceable by the department. This should be done if the land is sold via a joint development agreement. PAN should be mentioned in all transactions, applicable under this section. Sub-registrars have been sending us a lot of information of TDS collection and cases of evasion too, but now there?s a format which should be adhered to. This format makes it easy for IT sleuths to track cases.?
Inspector-general of registration and commissioner of stamps AS Saleem said: ?Out of the Rs 5,260 crore revenue the stamps and registration department collected last fiscal, 60-70% was collected from Bangalore Urban alone. Another Rs 500 crore comes from optional registerable documents like shares and loan bonds. We?re also trying to levy stamp duty on imported goods.?
What the law says
Section 194-IA of Income Tax Act ? payment on transfer of certain immovable property other than agricultural land states: Any person, being a transferee, responsible for paying to a resident (transferor), any sum by way of consideration for transfer of any immovable property (other than agricultural land), shall at the time of credit of such sum to the account of the transferor or at the time of payment of such sum in cash or by issue of a cheque or draft or by any other mode, whichever is earlier, deduct an amount equal to 1%of such sum as income-tax.
Note these
Who should pay TDS: buyer of the property
When it should be paid: before registering the property
Sub-registrars must note the permanent address and PAN of seller
In numbers
In 2010-11, 12,000 properties were registered across the state
June 11, 2013 ? A new study finds that stroke patients' brains show strong cortical motor activity when observing others performing physical tasks -- a finding that offers new insight into stroke rehabilitation.
Using functional magnetic resonance imaging (fMRI), a team of researchers from USC monitored the brains of 24 individuals -- 12 who had suffered strokes and 12 age-matched people who had not -- as they watched others performing actions made using the arm and hand that would be difficult for a person who can no longer use their arm due to stroke -- actions like lifting a pencil or flipping a card.
The researchers found that while the typical brain responded to the visual stimulus with activity in cortical motor regions that are generally activated when we watch others perform actions, in the stroke-affected brain, activity was strongest in these regions of the damaged hemisphere, and strongest when stroke patients viewed actions they would have the most difficulty performing.
Activating regions near the damaged portion of the brain is like exercising it, building strength that can help it recover to a degree.
"Watching others perform physical tasks leads to activations in motor areas of the damaged hemisphere of the brain after stroke, which is exactly what we're trying to do in therapy," said Kathleen Garrison, lead author of a paper on the research. "If we can help drive plasticity in these brain regions, we may be able to help individuals with stroke recover more of the ability to move their arm and hand."
Garrison, who completed this research while studying at USC and is currently a post-doctoral researcher at the Yale University School of Medicine, worked with Lisa Aziz-Zadeh of the USC Brain and Creativity Institute and the Division of Occupational Science and Occupational Therapy; Carolee Winstein, director of the Motor Behavior and Neurorehabilitation Laboratory in the Division of Biokinesiology and Physical Therapy at USC; and former USC doctoral student Sook-Lei Liew and postdoctoral researcher Savio Wong.
Their research was posted online ahead of publication by the journal Stroke on June 6.
Using action-observation in stroke rehabilitation has shown promise in early studies, and this study is among the first to explain why it may be effective.
"It's like you're priming the pump," Winstein said. "You're getting these circuits engaged through the action-observation before they even attempt to move." The process is a kind of virtual exercise program for the brain that prepares you for the real exercise that includes the brain and body.
The study also offers support for expanding action-observation as a therapeutic technique -- particularly for individuals who have been screened using fMRI and have shown a strong response to it.
"We could make videos of what patients will be doing in therapy, and then have them watch it as homework," Aziz-Zadeh said. "In some cases, it could pave the way for them to do better."
Having a support system of people and resources is very important when advocating for your child's special education. Having to navigate the education system alone and with few resources can be an overwhelming experience. However, there are ways to find others who have insight, advice and ways to support you and your child's journey through school. Listen to The Inclusive Class Podcast on Friday, June 14 at 9 AM EST when we interview Wendy Kruse.?Wendy Kruse is a military spouse, mother to two beautiful girls, and the CEO of the Military Special Needs Network. She became an advocate in 2006 when her youngest daughter was diagnosed with severe neurological and developmental delays. Having experienced the overwhelming feelings that confront parents after receiving a devastating diagnosis, Wendy knows how challenging it can be to navigate the world of special needs in the military and the myriad of decisions that we are faced with. As a result, Wendy founded the Military Special Needs Network to provide resources and support for others.
Using her knowledge and insight, Wendy will share ways in which she built her support system, which eventually evolved into the organization that it is today. She will discuss the importance of creating a network of resources and people for her child with special needs, her family and her own well-being.
For more information about the Military Special Needs, go to www.militaryspecialneedsnetwork.com.
Tune in for our live show on June 14th at 9 AM EST or download the show to listen to later!?
Apple debuted the next generation of iOS yesterday at WWDC and now you can watch Jony Ive's 7 minute iOS 7 introduction video. "True simplicity is derived from so much more than just the absences of clutter or ornamentation," Ive explains. "It's about bringing order to complexity."
June 11, 2013 ? Advanced metastatic melanoma is a disease that has proven difficult to eradicate. Despite the success of melanoma-targeting drugs, tumors inevitably become drug resistant and return, more aggressive than before. In the current issue of the journal Cancer Cell, however, researchers at The Wistar Institute describe how they increase the effectiveness of anti-melanoma drugs by combining anticancer therapies with diabetes drugs.
Their studies, conducted in cell and animal models of melanoma, demonstrate that the combined therapy could destroy a subset of drug-resistant cells within a tumor.
"We have found that the individual cells within melanoma tumors are not all identical, and tumors contain a sub-population of cells that are inherently drug resistant, which accounts for the fact that advanced melanoma tumors return no matter how much the tumor is depleted," said Meenhard Herlyn, D.V.M., D.Sc., professor and director of Wistar's Melanoma Research Center. "We found that these slow-growing, drug-resistant cells are marked by a high rate of metabolism, which makes them susceptible to diabetes therapeutics."
"Our findings suggest a simple strategy to kill metastatic melanoma -- regardless of cell type within the tumor -- by combining anticancer drugs with diabetes drug," Herlyn said. "The diabetes drug puts the brakes on the cells that would otherwise repopulate the tumor, thus allowing the anticancer drug to be more effective."
In the Cancer Cell article, the researchers describe how various anticancer drugs, including cisplatin and the targeted therapy vemurafenib, which targets melanomas with the BRAF mutation, become more effective when co-delivered with phenformin. According to Herlyn, the researchers used the diabetes drug phenformin in their studies, but they are now working with colleagues to develop a clinical trial using a drug with less toxic side effects.
Melanoma is the deadliest, most aggressive form of skin cancer. Melanoma rates continue to remain on the rise, and the average patient age continues to decrease. While surgical treatment of early melanoma leads to 90 percent cure rates, advanced melanoma is notoriously resistant to chemotherapy and has a tendency to metastasize, or spread, throughout the body. Nearly half of all melanomas contain BRAF mutations, which led to the successful creation and approval of new BRAF-targeting drugs.
In 2010, Herlyn and his colleagues published findings that changed the way scientists look at tumor cells. Melanoma tumors were, as they described, heterogeneous. That is, they contained multiple populations of cells, including the so-called JARID1B cells, which their research suggested was responsible for allowing tumors to survive drug therapy. According to Herlyn, these slow-growing JARID1B cells represent only one to five percent of the cells in a tumor, yet readily divide into the fast-growing cells that are the hallmark of advanced melanoma.
Amazingly, these cells were remarkably resistant to drug therapies. "JARIRD1B cells shrug off chemotherapies and targeted drug inhibitors, regardless of their mode of action," Herlyn said.
"These are not dormant cells -- they divide once every six or seven weeks as opposed to every other day like the rest of the melanoma cells," Herlyn explained. "These slow-growing cells are apparently kept in check by the rest of the tumor, somehow--indeed, if you remove them from a tumor, they grow like crazy."
Working with Wistar's Proteomics Facility, the Herlyn laboratory surveyed JARID1B's proteome (that is, the sum total of all the proteins these cells produce), and found that these cells were on metabolic overdrive. Despite the fact that they hardly seemed to grow and divide, they were continually synthesizing glucose, which is then used to produce chemical energy.
Fortunately, an entire field of study has been created to combat cells that produce glucose -- diabetes. Using phenformin, a drug first created nearly a half century ago, the researchers demonstrated it was possible to deprive melanoma tumors of the metabolic dynamos that allow melanoma to survive therapy.
According to Herlyn, Wistar's Melanoma Research Center is working with their clinical partners to develop a clinical trial to apply their research findings to patients with advanced melanoma.
The research was funded by NIH grants CA25874, CA047159, and CA10815, a grant from the Dr. Miriam and Scheldon G. Adelson Medical Research Foundation, and grants from the German research foundation, Deutsche Forschungsgemeinschaft (DFG).
In-Q-Tel (IQT) is a not-for-profit venture capital group that?helps the NSA and other agencies hunt for?startup and young companies?that develop core technology for the U.S. intelligence community. These young companies are often outside the reach of the intelligence community — about 70 percent of them have never worked with the government before. IQT often co-invests with venture capital groups, giving the CIA, NSA and other intelligence agencies access to the most new and innovative technologies on the market. IQT is highly influential with the startup community and serves as an arm for intelligence operations. That?s evident in how it markets itself to potential employees: The bottom line is that In-Q-Tel accelerates the Intelligence Community?s access to cutting-edge technology. We have had significant impact in supporting the IC mission, but we know that the only way to maintain our success is to continually attract top-notch talent from a wide variety of industries and professions. We are constantly reaching out to individuals who can add their creativity to the task before us ? improving our nation?s security. What The NSA Is Looking For Job listings for IQT show the sophistication of the technology that the intelligence community is seeking: Top-secret clearance is needed for the people applying to work at IQT as a systems engineer. This is the job that does the technical work of transferring the startups and other porfolio companies to the intelligence community. These technologies include but are not limited to geospatial analytic tools, video analytic products, large-scale data systems, multilingual translation tools, security and mobility products. IQT lists ?social network analysis,? as an area of focus for an intern in software engineering out of its Menlo Park office. In the job post, knowledge of OpenStack is listed as a plus. OpenStack has gained importance with the NSA for integrating the infrastructures of its various different agencies. It looks like the intelligence community needs better messaging and identity systems. A job listing for a member of the technical staff states they need someone ?to define technology requirements and recommend solutions for identity and authentication for a secure email and messaging platform.? A job posting for a strategic advisor shows the extent that IQT seeks out tech companies with disruptive technologies. The job essentially requires the person to seek out companies that are doing some of the most extraordinary work in Silicon Valley. The posting cites advanced analytics, data visualization,
The body electric: Researchers move closer to low-cost, implantable electronicsPublic release date: 10-Jun-2013 [ | E-mail | Share ]
Contact: Pam Frost Gorder Gorder.1@osu.edu 614-292-9475 Ohio State University
Aiding organ transplants to be first application of new technology
COLUMBUS, OhioNew technology under development at The Ohio State University is paving the way for low-cost electronic devices that work in direct contact with living tissue inside the body.
The first planned use of the technology is a sensor that will detect the very early stages of organ transplant rejection.
Paul Berger, professor of electrical and computer engineering and physics at Ohio State, explained that one barrier to the development of implantable sensors is that most existing electronics are based on silicon, and electrolytes in the body interfere with the electrical signals in silicon circuits. Other, more exotic semiconductors might work in the body, but they are more expensive and harder to manufacture.
"Silicon is relatively cheap it's non-toxic," Berger said. "The challenge is to bridge the gap between the affordable, silicon-based electronics we already know how to build, and the electrochemical systems of the human body."
In a paper in the journal Electronics Letters, Berger and his colleagues describe a new, patent-pending coating that that they believe will bridge that gap.
In tests, silicon circuits that had been coated with the technology continued to function, even after 24 hours of immersion in a solution that mimicked typical body chemistry.
The project began when Berger talked to researchers in Ohio State's Department of Biomedical Engineering, who wanted to build an insertable sensor to detect the presence of proteins that mark the first signs of organ rejection in the body. They were struggling to make a working protein sensor from gallium nitride.
"We already have sensors that would do a great job at detecting these proteins, but they're made out of silicon. So I wondered if we could come up with a coating that would protect silicon and allow it to function while it directly touched blood, bodily fluids or living tissue," Berger said.
In the body, electrolytes such as sodium and potassium control nerves and muscles and maintain hydration. They do this by carrying a positive or negative electric charge that spurs important chemical reactions. But those same charges make the electrolytes attractive to silicon, which will readily absorb them. Once inside, the charges alter the electronic behavior of the silicon so that the readings of a sensor can't be trusted.
In the study, Berger's team tested whether electrolytes could be blocked from entering silicon with a layer of aluminum oxide.
The researchers submerged the coated test sensors in fluid for up to 24 hours, removed them from the solution, and then ran a voltage across them to see if they were working properly. The tests showed that the oxide coating effectively blocked electrolytes from the solution so the sensors remained fully functional.
Once developed, a device using this technology could detect certain proteins that the body produces when it's just beginning to reject a transplanted organ. Doctors would insert a needle into the patient's body near the site of the implanted organ. Silicon sensors on the needle would detect the protein, and doctors would know how to tailor the patient's dosage of anti-rejection drugs based on the sensor readings.
The work represents a first step toward fabricating devices that could be implanted in the body long-term, Berger said.
Though the current study describes a silicon sensor coated with aluminum oxide, he envisions that other devices could utilize coatings made from other materials such as titanium. Such coatings could even be tailored to boost the performance of sensors or other biomedical devices.
In particular, Berger sees a potential use for coated polymer semiconductors that goes beyond sensing chemicals in the body. He suspects that such semiconductors could replace nerves in the body that have been damaged by disease or injury.
"We could replace a damaged nerve with an artificial neuron and restore functionality immediately, and that's a really exciting possibility," he said.
Berger's team is working with Ohio State researchers Tom Rosol, professor of veterinary biosciences, and Phillip Popovich, professor of neuroscience, to explore that possibility.
###
Coauthors on the Electronics Letters paper included former doctoral students Anisha Ramesh, Fang Ren, Patricia Casal and Samit Gupta; current doctoral student in biomedical engineering Andrew Theiss, and Stephen Lee, associate professor of biomedical engineering. The university will license this technology for further development.
Contact: Paul R. Berger, (614) 247-6235; pberger@ieee.org
Written by Pam Frost Gorder, (614) 292-9475; Gorder.1@osu.edu
[ | E-mail | Share ]
?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
The body electric: Researchers move closer to low-cost, implantable electronicsPublic release date: 10-Jun-2013 [ | E-mail | Share ]
Contact: Pam Frost Gorder Gorder.1@osu.edu 614-292-9475 Ohio State University
Aiding organ transplants to be first application of new technology
COLUMBUS, OhioNew technology under development at The Ohio State University is paving the way for low-cost electronic devices that work in direct contact with living tissue inside the body.
The first planned use of the technology is a sensor that will detect the very early stages of organ transplant rejection.
Paul Berger, professor of electrical and computer engineering and physics at Ohio State, explained that one barrier to the development of implantable sensors is that most existing electronics are based on silicon, and electrolytes in the body interfere with the electrical signals in silicon circuits. Other, more exotic semiconductors might work in the body, but they are more expensive and harder to manufacture.
"Silicon is relatively cheap it's non-toxic," Berger said. "The challenge is to bridge the gap between the affordable, silicon-based electronics we already know how to build, and the electrochemical systems of the human body."
In a paper in the journal Electronics Letters, Berger and his colleagues describe a new, patent-pending coating that that they believe will bridge that gap.
In tests, silicon circuits that had been coated with the technology continued to function, even after 24 hours of immersion in a solution that mimicked typical body chemistry.
The project began when Berger talked to researchers in Ohio State's Department of Biomedical Engineering, who wanted to build an insertable sensor to detect the presence of proteins that mark the first signs of organ rejection in the body. They were struggling to make a working protein sensor from gallium nitride.
"We already have sensors that would do a great job at detecting these proteins, but they're made out of silicon. So I wondered if we could come up with a coating that would protect silicon and allow it to function while it directly touched blood, bodily fluids or living tissue," Berger said.
In the body, electrolytes such as sodium and potassium control nerves and muscles and maintain hydration. They do this by carrying a positive or negative electric charge that spurs important chemical reactions. But those same charges make the electrolytes attractive to silicon, which will readily absorb them. Once inside, the charges alter the electronic behavior of the silicon so that the readings of a sensor can't be trusted.
In the study, Berger's team tested whether electrolytes could be blocked from entering silicon with a layer of aluminum oxide.
The researchers submerged the coated test sensors in fluid for up to 24 hours, removed them from the solution, and then ran a voltage across them to see if they were working properly. The tests showed that the oxide coating effectively blocked electrolytes from the solution so the sensors remained fully functional.
Once developed, a device using this technology could detect certain proteins that the body produces when it's just beginning to reject a transplanted organ. Doctors would insert a needle into the patient's body near the site of the implanted organ. Silicon sensors on the needle would detect the protein, and doctors would know how to tailor the patient's dosage of anti-rejection drugs based on the sensor readings.
The work represents a first step toward fabricating devices that could be implanted in the body long-term, Berger said.
Though the current study describes a silicon sensor coated with aluminum oxide, he envisions that other devices could utilize coatings made from other materials such as titanium. Such coatings could even be tailored to boost the performance of sensors or other biomedical devices.
In particular, Berger sees a potential use for coated polymer semiconductors that goes beyond sensing chemicals in the body. He suspects that such semiconductors could replace nerves in the body that have been damaged by disease or injury.
"We could replace a damaged nerve with an artificial neuron and restore functionality immediately, and that's a really exciting possibility," he said.
Berger's team is working with Ohio State researchers Tom Rosol, professor of veterinary biosciences, and Phillip Popovich, professor of neuroscience, to explore that possibility.
###
Coauthors on the Electronics Letters paper included former doctoral students Anisha Ramesh, Fang Ren, Patricia Casal and Samit Gupta; current doctoral student in biomedical engineering Andrew Theiss, and Stephen Lee, associate professor of biomedical engineering. The university will license this technology for further development.
Contact: Paul R. Berger, (614) 247-6235; pberger@ieee.org
Written by Pam Frost Gorder, (614) 292-9475; Gorder.1@osu.edu
[ | E-mail | Share ]
?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.